On Jan. 14, Schering-Plough released preliminary results of its ENHANCE clinical trial, finding that Vytorin (Zocor/Zetia) did nothing more than generic Zocor alone to slow the progression of plaques—in the carotid arteries of a smallish number of patients with a familial form of hypercholesterolemia who had previously been on statins.
Figuring out journal ads’ slip ‘n’ slide
May 1, 2008
3:52 pm
PERQ/HCI data suggest that the slowdown in journal ad sales is hitting both medical-surgical journals and specialty titles as the professional ad spend fell again in 2007. What’s behind the slide in spending? How can journals hold their ground?
One of the fundamental challenges facing pharmaceutical companies is finding a balance between developing and manufacturing lifesaving medications and making money for shareholders.
The pharmaceutical industry’s character—its products, messages, promo channels and even its audiences—have been determined by governmental regulation and trade conventions practiced by media and manufacturers.
Joe Jimenez isn’t interested in lamenting the state of the industry. He’s focused on one thing: adapting Novartis to thrive in a mercurial environment.
Slight gains in ad spending were reported among only three of the eight specialty markets with laboratory journals leading the pack. PERQ/HCI’s Eugene M. May reports
It’s Asthma and Allergy Awareness Month and the seasonal allergies category is as congested as ever. But a slew of patent expirations poses a greater concern than the fierce competition.